文献速递腹部技术与安全CT

双层光谱探测器CT定量指标在胰腺神经内分泌肿瘤与神经内分泌癌鉴别中的效用

Utility of Quantitative Metrics From Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma.
PubMed 文献 · AJR Am J Roentgenol · 2022-01-19

本回顾性研究纳入104例病理确诊胰腺神经内分泌肿瘤(NEN)患者,其中神经内分泌肿瘤(NET)89例、神经内分泌癌(NEC)15例,分析多期双层光谱探测器CT(DLCT)定量指标。门静脉期碘浓度(IC)、有效原子序数(Zeff)及CT衰减值是NEC的独立预测因子,IC与Zeff联合预测NEC的AUC为0.921,敏感度93.33%、特异度80.90%。DLCT定量指标较常规CT衰减值和定性特征更能改善NET与NEC的鉴别。

要点

  • 门静脉期IC和Zeff是鉴别胰腺NET与NEC的独立预测因子,两者联合AUC达0.921。
  • 门静脉期IC联合Zeff预测NEC的敏感度为93.33%、特异度为80.90%。
  • 鉴别G3 NET与NEC时,门静脉期IC的AUC为0.789,衰减值的AUC为0.647。

核心结论

  • DLCT定量指标的纳入较常规CT衰减值和定性特征更能改善NET与NEC的鉴别。

研究设计与样本

  • 回顾性研究纳入104例病理确诊的胰腺NEN患者(平均年龄51±13岁;52例女性、52例男性;89例NET,包括22例G1、48例G2、19例G3;15例NEC),在活检或切除前15天内行多期DLCT检查。

诊断标准与关键数值

  • 门静脉期IC中位数NEC 1.3 mg/mL vs NET 2.7 mg/mL,预测NEC的AUC为0.897;门静脉期Zeff中位数NEC 8.1 vs NET 8.6,AUC为0.884;门静脉期衰减值中位数NEC 78.2 HU vs NET 113.5 HU,AUC为0.855;IC与Zeff联合AUC为0.921,预测概率敏感度93.33%、特异度80.90%;鉴别G3 NET与NEC时,门静脉期IC中位数2.0 vs 1.3 mg/mL(AUC=0.789),门静脉期衰减值均值90.3 vs 78.2 HU(AUC=0.647)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The 2019 WHO classification of digestive system tumors separates neuroendocrine neoplasms (NENs) into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), which are considered to represent pathologically distinct entities warranting different management approaches. Dual-layer spectral-detector CT (DLCT) may aid their differentiation through specific material decomposition. OBJECTIVE. The purpose of this study was to assess the utility of quantitative metrics derived from DLCT for the differentiation of pancreatic NET and NEC. METHODS. This retrospective study included 104 patients (mean age, 51 ± 13 [SD] years; 52 women, 52 men) with pathologically confirmed NEN (89 NET, including 22 grade 1, 48 grade 2, and 19 grade 3; 15 NEC) who underwent multiphase DLCT within 15 days before biopsy or resection. Two radiologists independently placed ROIs to record tumor attenuation, iodine concentration (IC), and effective atomic number (Zeff) across phases and assessed qualitative features (composition, homogeneity, margins, calcifications, main pancreatic duct dilatation, vascular invasion, lymphadenopathy). Interobserver agreement was assessed. Mean and median values of both readers' measurements were obtained for quantitative measures; consensus was reached for qualitative features. NET and NEC were compared using multivariable regression analysis and ROC analysis. RESULTS. Interobserver agreement, expressed as intraclass correlation coefficients, ranged from 0.869 to 0.992 for quantitative metrics and, expressed as kappa coefficients, ranged from 0.723 to 0.816 for qualitative features. In multivariable analysis of qualitative and quantitative features, significant independent predictors of NEC (p < .05) were IC in the portal venous phase (median, 1.3 mg/mL for NEC vs 2.7 mg/mL for NET), Zeff in the portal venous phase (median, 8.1 vs 8.6), and attenuation in the portal venous phase (median, 78.2 vs 113.5 HU). AUC for predicting NEC was 0.897 for IC, 0.884 for Zeff, 0.921 for combination of IC and Zeff, and 0.855 for attenuation. Predicted probability based on a combination of IC and Zeff achieved sensitivity of 93.33% and specificity of 80.90% for predicting NEC. Significant independent predictors (p < .05) for differentiating grade 3 NET and NEC were IC (median, 2.0 vs 1.3 mg/mL; AUC = 0.789) and attenuation (mean, 90.3 vs 78.2 HU; AUC = 0.647), both measured in the portal venous phase. CONCLUSION. Incorporation of DLCT metrics improves differentiation of NET and NEC compared with conventional CT attenuation and qualitative features. CLINICAL IMPACT. DLCT may help select patients with pancreatic NENs for platinum-based chemotherapies.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Wang, Hu, Shi, et al. Utility of Quantitative Metrics From Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma. AJR Am J Roentgenol. 2022. PMID: 35043668. doi:10.2214/AJR.21.27017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。